S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

NovoCure Stock Forecast, Price & News

-2.92 (-4.17%)
(As of 01/21/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
752,830 shs
Average Volume
946,423 shs
Market Capitalization
$6.97 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter.

NovoCure logo

About NovoCure

NovoCure Ltd. develops treatment for tumors. Its platform is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.


Competing by Connecting - Yahoo Finance
January 21, 2022 |  finance.yahoo.com
Why Novocure Stock Is Jumping Today
January 20, 2022 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$494.37 million
Cash Flow
$0.31 per share
Book Value
$4.68 per share


Net Income
$19.81 million
Pretax Margin




Free Float
Market Cap
$6.97 billion

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End


Overall MarketRank

2.30 out of 5 stars

Medical Sector

286th out of 1,419 stocks

Surgical & Medical Instruments Industry

30th out of 130 stocks

Analyst Opinion: 3.2Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

NovoCure (NASDAQ:NVCR) Frequently Asked Questions

Is NovoCure a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NovoCure stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVCR, but not buy additional shares or sell existing shares.
View analyst ratings for NovoCure
or view top-rated stocks.

How has NovoCure's stock price been impacted by COVID-19?

NovoCure's stock was trading at $67.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NVCR stock has decreased by 0.3% and is now trading at $67.18.
View which stocks have been most impacted by COVID-19

When is NovoCure's next earnings date?

NovoCure is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for NovoCure

How can I listen to NovoCure's earnings call?

NovoCure will be holding an earnings conference call on Thursday, February 24th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were NovoCure's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) issued its quarterly earnings results on Thursday, October, 28th. The medical equipment provider reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.07. The medical equipment provider had revenue of $133.61 million for the quarter, compared to the consensus estimate of $141.22 million. NovoCure had a negative net margin of 4.94% and a negative trailing twelve-month return on equity of 6.50%. NovoCure's revenue was up .7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.09 earnings per share.
View NovoCure's earnings history

What price target have analysts set for NVCR?

6 brokers have issued 1 year price targets for NovoCure's shares. Their forecasts range from $70.00 to $250.00. On average, they anticipate NovoCure's share price to reach $154.83 in the next year. This suggests a possible upside of 130.5% from the stock's current price.
View analysts' price targets for NovoCure
or view top-rated stocks among Wall Street analysts.

Who are NovoCure's key executives?

NovoCure's management team includes the following people:

What is Asaf Danziger's approval rating as NovoCure's CEO?

17 employees have rated NovoCure CEO Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among NovoCure's employees.

What other stocks do shareholders of NovoCure own?

What is NovoCure's stock symbol?

NovoCure trades on the NASDAQ under the ticker symbol "NVCR."

Who are NovoCure's major shareholders?

NovoCure's stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (9.26%), Frontier Capital Management Co. LLC (0.42%), Taylor Frigon Capital Management LLC (0.04%), Exchange Traded Concepts LLC (0.03%), Sciencast Management LP (0.01%) and Cutler Group LP (0.00%). Company insiders that own NovoCure stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends for NovoCure

Which institutional investors are buying NovoCure stock?

NVCR stock was acquired by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Frontier Capital Management Co. LLC, Exchange Traded Concepts LLC, Sciencast Management LP, Lattice Capital Management LLC, Taylor Frigon Capital Management LLC, AdvisorNet Financial Inc, and IFP Advisors Inc.
View insider buying and selling activity for NovoCure
or or view top insider-buying stocks.

How do I buy shares of NovoCure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NovoCure's stock price today?

One share of NVCR stock can currently be purchased for approximately $67.18.

How much money does NovoCure make?

NovoCure has a market capitalization of $6.97 billion and generates $494.37 million in revenue each year. The medical equipment provider earns $19.81 million in net income (profit) each year or ($0.27) on an earnings per share basis.

How many employees does NovoCure have?

NovoCure employs 1,023 workers across the globe.

What is NovoCure's official website?

The official website for NovoCure is www.novocure.com.

Where are NovoCure's headquarters?

How can I contact NovoCure?

NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 441534756700 or via email at [email protected].

This page was last updated on 1/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.